Anish Patel
Gastroenterology · Fort Sam Houston, TXNPI 1649476466
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,049,445 of the $1,318,436 with a category attached, or 79.6%. 29 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 28.9% of the total. 2025 is the largest year on record at $430,291, 4.7 times the $90,737 reported in 2019. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,360 payments — averaging $969.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$381K
- Johnson & Johnson$301K
- E.r. Squibb & Sons, L.L.C.$180K
- Lilly USA, LLC$150K
- AbbVie$103K
- Janssen Scientific Affairs, LLC$91K
- plus $113K from 23 others
Across 9 payments — averaging $5896.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$34K
- E.r. Squibb & Sons, L.L.C.$19K
What the payments were for
- Consulting fees$26,7402%
- Speaking & faculty fees$1,049,44580%
- Travel & lodging$208,96816%
- Food & beverage$33,2623%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 356 | $381,025 |
| Johnson & Johnson | 255 | $301,087 |
| E.r. Squibb & Sons, L.L.C. | 142 | $180,410 |
| Lilly USA, LLC | 179 | $149,891 |
| AbbVie | 135 | $102,938 |
| Janssen Scientific Affairs, LLC | 100 | $90,519 |
| Phathom Pharmaceuticals, Inc. | 60 | $59,605 |
| Daiichi Sankyo Inc. | 29 | $27,598 |
| Pfizer | 31 | $14,918 |
| Bristol Myers Squibb | 38 | $5,642 |
| Gilead | 4 | $2,516 |
| Boston Scientific | 3 | $300 |
| Regeneron Healthcare Solutions, Inc. | 4 | $300 |
| Laborie Medical Technologies Corp. | 2 | $210 |
| Medtronic | 2 | $170 |
| ERBE USA Inc | 2 | $167 |
| Madrigal Pharmaceuticals | 2 | $151 |
| Calyxo, Inc. | 1 | $145 |
| Olympus America Inc. | 2 | $139 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| Shire North American Group Inc | 1 | $123 |
| Sanofi | 3 | $114 |
| American Regent | 2 | $109 |
| Covidien LP | 1 | $81 |
| Fresenius Kabi USA, LLC | 1 | $53 |
| Intercept Pharmaceuticals, Inc. | 1 | $27 |
| Ironwood Pharmaceuticals, Inc | 1 | $26 |
| Merck | 1 | $24 |
| QOL Medical, LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,318,436 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Fort Sam Houston
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Timothy RitterSouthlake$961K
- Parvez MantryDallas$958K
- Nadege GunnWaco$933K
- Brooks CashHouston$867K
- Mohamed OthmanHouston$777K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.